MAOIs: 2020 update

by | Last updated Oct 17, 2021 | Published on Apr 23, 2019 | Anti-Depressants, MAOIs, Recent Commentaries


There have been a number of reviews about the pharmacology and clinical therapeutics of MAOIs in the last decade: yet, most standard medical texts still have incorrect and misleading information and opinion. I have convened an international group of more than 100 eminent experts who are interested in furthering knowledge and increasing utilisation of MAOIs. There is extensive concern in that group about their under-usage, the lack of teaching about them, and the fact that in many countries their availability is lessening or has even ceased.

I am pleased to announce that my group has now published a position statement on the safety and under-usage of MAOIs which appears as an editorial in the journal CNS spectrums. It has been endorsed by more than 80 eminent specialists and researchers from all over Europe and North America [link]. One can only hope that the weight of opinion of so many eminent people will have some influence — but what is even more important is that everybody reading this spreads the word throughout their networks.

Many in this field consider that under-usage of MAOIs is leading to a great deal of increased suffering and also unnecessary deaths by suicide.

The relevant members of this class (irreversible, non-selective, MAOIs) are; tranylcypromine, phenelzine, isocarboxazid, and selegiline.

Selegiline, being selective for MAO-B, probably does not elevate dopamine as much as the other non-selective MAOIs, PET studies indicate it does not inhibit brain levels of MAO-A to a substantial extent at ‘selective’ dose levels (1, 2). That fits with its seemingly lesser effectiveness, unless it is used at higher (oral) doses of 30-60 mg.

MAOIs have all been out of patent for decades, and were, for a long time, inexpensive drugs. However, in the last decade the price of some of them, in various countries, has gone up by a hundred-fold or more, for no obvious or justifiable reason (tranylcypromine now costs GBP >300 for only 30 tabs, meaning that a typical one-month supply is approaching GBP 2,000). It has been suggested that price-gouging, corruption, and price-fixing may be the explanation, and in view of the recent Washington Post revelations in the USA about price-fixing of generic drugs, that is a plausible explanation. Some are fighting back, like Civica Rx. In the US Civica Rx has been formed, it is a substantively capitalised enterprise connected with many US hospitals which seeks to source or produce generic drugs on a not-for-profit basis. That indicates how bad a large number of American hospitals think the situation has become.

I would also note that individual patients can fight back too. UK customs seem to have no problem with people ordering drugs from abroad for personal medical use. I have a number of people who have contacted me via the website who this without a problem. More about this another time [link]\.

One of the prime functions of my website is to provide information about MAOIs. I have published a number of scientific papers about these drugs (3-11) and I am widely regarded as an expert about them, and the interactions between psychotropic drugs generally (i.e. ST).

This updated series of commentaries will provide the latest information concerning their pharmacology and therapeutic use. It will also suggest ways in which consumers of medical services can influence developments and improve the availability of drugs. Patient groups that are not connected to, or financed by, ‘big pharma’ have an important part to play and it would be helpful if they were mobilised and coordinated.


We should note the early 1960s reviews about MAOIs by Atkinson, Atchley, Lesse, (12-15), and Cole (16), Cole’s was updated in 2002 (17).

Other more ‘recent’ (it is a relative term) reviews are: (6, 7, 18-43). The number of reviews certainly suggests an underlying ground-swell of interest.

Although these reviews are ‘noteworthy’ that does not infer I recommend or endorse them all: only some are useful, and most of them are not without significant omissions and errors (many of these errors relate to ST and tyramine, my special areas of expertise). Indeed, the less than perfect knowledge about MAOIs was one of my motivating factors when I decided to form the international experts group.

Medical science publishing has become so poorly governed that it is difficult for most readers to ascertain what is reliable and worth reading — therefore experts such as myself need to state plainly when the material they are referring to is not considered reliable, even if that does discombobulate a few people, however eminent or expert they might be considered to be.

That reminds me of the quote from the Nobel prize-winning physicist, Neils Bohr:

An expert is a man who has made all the mistakes it is possible to make, but only in a very narrow field

I used that quote when acting as an expert witness in a court case. I turned to the judge and said: ‘and I, your honour, am definitely an expert’. It diffused a situation and made the judge laugh.

Therefore, I cannot omit special mention of the particularly poor review from 2007 by Krishnan (cited by some, x7 in PubMed, and x73 in Google Scholar) which was the review that appears to have qualified him for writing the American Psychiatric Association psychopharmacology textbook chapter on MAOIs (which I presume was ghost-written by the same people as ‘his’ review), about which I have made severe criticisms previously — such people are not worthy of respect. His 2007 review article is clearly ghost written and has serious errors. It is a classic example of the blind leading the blind, and of how careful one has to be when reading the literature, because so much is such poor quality, and ‘written’ by people who have no substantive claim to be experts (44). I will say no more, except that if he continues writing more articles like this he will, eventually, become a ‘Bohr’ accredited expert.

Caveat lector.

An aside

I must slip in a quick story, necessarily abbreviated as it is, about the MAOI book chapter written by a famous London teaching hospital psychiatrist — it was very poor. Later, when he was working at the same teaching-hospital as me, I became responsible, temporarily, for his patients, and cured one of them (who had already been in hospital for two months), in the 10 days he was away, with tranylcypromine. When he returned, he was delighted with the (obvious) improvement, but when he realised it was caused by tranylcypromine, he burst into an anxious sweat and ceased the treatment. The patient had no side-effects! Needless to say, the doctors who worked with him regularly told me, subsequently, that he never used MAOIs — but, he wrote the book chapter about them! As Shaw said:

Remember those who can, do; those who can’t, teach (45)

I remember one day in the coffee room we added a few more stages to Shaw’s maxim, ‘… and those can’t teach write books, and those who can’t write books do drug-comparison trials’

Although that was Coffee-room humour, there is an element of truth to it

Now you know why I sometimes call psychiatrists timorous, and even pusillanimous (46).

Basic pharmacology

It is worth reminding our-selves of a few basics that are especially relevant when considering MAOIs. From my perspective these are as follows.

First, drugs that have specific effects on only one transmitter are generally less effective, as exemplified by SSRIs, and NRIs like reboxetine.

Second, drugs with a true dual effect, and that may exclude duloxetine and venlafaxine (which fall short as NRIs) but certainly does include clomipramine, are almost certainly more potent.

Third, drugs that effect all three systems, i.e. including the Cinderella transmitter, dopamine (47), are even better.

The non-selective irreversible MAOIs are really the only drugs have that ‘triple effect’, and indeed appear to be the most powerful.

There have been mutterings about triple reuptake inhibitors, with various drugs in various stages of trials (e.g. Liafensine). Some have already ‘failed’. In my view this is an absurd idea, since we simply do not know what relative potencies in the different pathways are optimal. The chance of synthesising such a drug with an ideal ratio of potencies would be impossibly difficult, if not just plain impossible: a hiding to nothing. Furthermore, the optimal balance needed in different people and types of depression is sure to be different. Just use the infinitely flexible regime with sertraline, nortriptyline and methylphenidate, or similar (I am not stating that definitely works, or is definitely better, just that it’s the logical way to go about experimenting).

One might also point out that the KI potency that is associated with significant clinical activity for different drugs is largely unknown, that is why I used serotonin toxicity data, in this paper (48), to elucidate that question as far as serotonin is concerned. That indicates a KI potency in low single figures is necessary for significant clinical activity. That tells us that none of the TCAs are ‘dual-action’ except for clomipramine: and clomipramine has the best evidence for superior efficacy.

Non-MAOI dopaminergic drugs

What non-MAOI drugs are there that reliably elevate DA, that can be used either by themselves, or in combination? This is a relatively neglected area. One or two recent reviews advance the cause (49-51).

In summary, there is quite clearly persuasive evidence that various dopaminergic drugs (‘stimulant’ is a term that should be ‘retired’) can be used with care to effectively and safely augment MAOI response. And, in the spirit of respecting clinical experience, and elevating it to its appropriate place in forming opinion, one should note that a number of members of the International MAOI expert group would confidently endorse the potentially life-saving effectiveness of such intervention in patients with severe depression.


One long-used and often forgotten drug is the dopamine reuptake inhibitor methylphenidate: there is persuasive evidence, from a respected research group, that it can be specifically effective in melancholic depression (52, 53). A property it thus shares with MAOIs like TCP. Bupropion is hovering timorously in the wings, but it is only weakly dopaminergic and in my experience is only useful in a minority of cases, usually only as an augmenting agent. A nugget of obscure knowledge: few people appear to appreciate that sertraline has similar DAT potency as methylphenidate (54-56). Is this why the combination of sertraline and nortriptyline appears to be particularly effective? is it why sertraline seems to be cognitively better than other SSRIs? Is the similar in vitro potency of sertraline and methylphenidate translated into similar effectiveness in humans?

So many interesting, but unaddressed, research questions to be answered.

This discussion brings us to the important question of ‘neuroscience-based nomenclature’ (57-62). In other words, talking about drugs according to their pharmacological action, not according to the, sometimes arbitrary, names attached to them, often by the marketing arm of the pharmaceutical company, not pharmacologists. Just as tricyclic antidepressants are not a pharmacologically homogenous group, neither are the so-called ‘stimulant’ drugs.

Thus, discussions of drugs that might be added to MAOIs, on the general presumption that they are ‘stimulant’ amphetamine-like releasers and dopaminergic and ‘addictive’, and dangerous etc., are misleading.

This digression about ‘neuroscience-based nomenclature’ was triggered, on this occasion, because I looked again at the comment and useful mini-review by Shalom Feinberg ‘Combining stimulants with monoamine oxidase inhibitors’ (63). It is even more useful to reinterpret such data in the light of pharmacological function rather than arbitrary drug class names, and thus refine our consideration of the so-called ‘stimulants’ according to their precise mode of pharmacological action — the most obvious distinction being that most such drugs are releasers, mainly of dopamine, but also of NA, just as MDMA (ecstasy) is releaser of serotonin. However, methylphenidate acts as a reuptake inhibitor, in this case with a strong preference for dopamine, it is much weaker at the noradrenaline transporter — it has a 10 to 1 selectivity of dopamine over noradrenaline, and is it insignificantly potent at SERT (the serotonin transporter) (56, 64, 65). That means that no major adverse interaction is expected with MAOIs (nor is one observed), and particularly, there is no risk of serotonin toxicity.

Interactions and toxicity

Another slight digression is in order: my observations from a consideration of these kinds of serious drug interactions, and particularly my studies in serotonin toxicity, is that one can make a generalisation — it is this: interactions between MAOIs and releasers generally produce more profound perturbations of neurotransmission and greater toxicity than do interactions between MAOIs and reuptake inhibitors. This appears to be the case across all three neurotransmitter pathways, serotonin, noradrenaline, and dopamine. Presumably this tells us something about the production and regulation of neurotransmitters in these different pathways, and the system’s sensitivity to the perturbations thereof, but I have never seen any discussion of this most interesting question. It also suggests that if a dopaminergic agent is required, as an addition to an MAOI, then methylphenidate is theoretically the drug of choice. Modafinil will be discussed elsewhere, but may be regarded as a dopaminergic drug with useful alerting properties that is even safer in combination with MAOIs.

Dopamine: The Cinderella effect

Once upon a time a little orphan molecule called Dopar was adopted by a wicked uncle called Big P. Harmer: he was fat and greedy, and his wife was a selfish and dishonest; they had two children of their own, Serotee and Nora (who were mean and lazy and did hardly any work round the house and rarely helped other people). They mollycoddled and spoilt their own children and spent a lot of money on them and sent them to lots of beauty pageants, especially Serotee, who was pretty and fashionable. Poor little Dopar was confined to the house doing menial jobs and was neglected and forgotten: until one day …

I have written elsewhere about this puzzling neglect of dopamine in neuropharmacology research. My earliest recollection of relevant discussion about the role of dopamine in depression is the dimensional interpretation advanced by Van Praag (66, 67). In animals, even low doses of DA antagonists impair reward-related behaviours (68, 69). Therefore, one might suspect that quite small changes in dopamine transmission are clinically relevant. Reducing dopamine is bad for depression, increasing it is good. For further details on this question see the above referenced commentary ‘Bupropion: still hazy …’.

There is so much evidence that low dopamine activity is an important part of severe depression that one would have to regard the current fashion of using antipsychotic drugs, all of which lower dopamine levels, as being inadvisable, from a theoretical viewpoint. Personally, I think it is the dumbest thing psychiatrists have done in a long time, and the one based on the lowest-grade, and the most biased, evidence. Clearly, this new generation of antipsychotic drugs is one of the biggest money-earners for big Pharma (we are talking about hundreds of billions of dollars), in a time when new drugs are thin on the ground: I don’t think you have to look very far to see where the drive behind this, and misdirection about it, is coming from.

One can only speculate as to the reasons for this neglect of dopamine in research — incidentally, I do not think it is to do with the contents of the above paragraph, because I do not think they are that smart. It may be that concern relating to addiction has played a part in regulatory agencies discouraging research and approval of drugs elevating dopamine, a bit like cannabis and LSD. There was a report a while ago about a dopamine reuptake inhibitor that was discouraged because of concerns it might have the ‘side-effect’ of excessive libido, with the potential consequences that might entail. Such concerns may not be entirely unfounded, and one is reminded of the increasing problems being recognised with the direct dopamine agonists (like pramipexole), centring around gambling and inappropriate excess sexual activities. These have been reviewed recently in an article with the revealing title ‘Don’t ask, don’t tell’ (70). The slow emergence of recognition of such side effects reflects the general tendency of doctors to shy away from asking difficult questions, like questions relating to suicide and sexual activity. There may be a tendency for neurologists (who are the biggest users of such drugs) to be less ‘people-orientated’ (a polite way of saying ‘below average social skills’) and more inclined towards the perfectionist, or even obsessional, end of the personality spectrum. This may exacerbate the difficulties of collecting deeply personal information. I speak from experience: in the early stage of my career I worked in the sex therapy clinic, my co-therapist was the professor’s wife, and I gained experience in helping doctors-in-training interview patients about sexual matters).

Methylphenidate and methodology

The papers cited above by Prof Parker are not controlled trials. In my view that does not make them any less valuable. Readers may be aware that I have argued repeatedly that the supposed superiority of randomised controlled trials is seriously over-rated — I have written extensively about that elsewhere. In this context I would mention that Sir Austin Bradford Hill, a statistician, and a fellow who might well have got a Nobel prize for his work on smoking and cancer said:

Randomization and blinding [and statistical analysis] of studies is only necessary when treatment effects are small.

His report on occupational diseases of workers in the cotton mills contained multiple tables of data, but not one single statistical test! He stated explicitly that the differences were so obvious statistics were unnecessary.

You do not need an RCT to tell you that parachutes work (71).

Doctors and researchers have become hypnotised by statistics and P-values to the point of losing their ability to think scientifically. If the chronic P-value fiasco of the last 30 years doesn’t convince you of the value of Bayesian reasoning, then nothing will.

It is important for younger researchers and doctors to appreciate that experienced people regard careful systematic observations of clinical experience as being just as valuable as RCTs, often more valuable, especially for severe cases that are never adequately represented in clinical trials. Clinical trial methodologies, geared towards obtaining FDA approval for drugs, are usually ill-suited to answering the more sophisticated questions relevant to serious research. I expect that is why Prof Parker did not trouble to do a double-blind trial.

In conclusion

MAOIs appear to be the most powerful antidepressants we have for serious cases of depression, especially melancholic depression; including when ECT has failed. They are safe with, and compatible with, methylphenidate. These types of depression appear to have even more involvement of dopaminergic pathways that less severe illnesses, and therefore require drugs that boost all three neurotransmitters, but especially dopamine, without which full remission is unlikely. The long-running neglect of dopamine’s role is reflected in the irony that the only reuptake inhibitor that acts specifically on dopamine (methylphenidate) is not classified as an antidepressant; it deserves to be used more often in severe and melancholic depression.

Much of the above discussion emphasises the usefulness of neuroscience-based nomenclature which should have been instituted long ago (see my 2006 TCA review, Table 6)).

The scene is thus set for understanding how and why MAOIs are so important despite being unappreciated for so long, longer than Cinderella.


1. Fowler, JS, Logan, J, Volkow, ND, Shumay, E, et al., Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain. Neuropsychopharmacology, 2015. 40(3): p. 650-7.

2. Hirvonen, J, Kailajarvi, M, Haltia, T, Koskimies, S, et al., Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. Clin Pharmacol Ther, 2009. 85(5): p. 506-12.

3. Gillman, PK, A reassesment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths. J Neural Transm (Vienna), 2018. 125(11): p. 1707-1717.

4. Gillman, PK, New data on Metaxalone (Skelaxin) and serotonin toxicity (serotonin syndrome): warning of potential for fatalities if combined with serotonin re-uptake inhibitors. PsychoTropical Commentaries, 2018. 18(6): p. 22-32.

5. Gillman, PK, Monoamine oxidase inhibitors: A review concerning dietary tyramine and drug interactions. PsychoTropical Commentaries, 2016. 16(8): p. 1-99 Available at: Accessed June 17, 2016.

6. Gillman, PK, Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. J Clin Psychopharmacol, 2011. 31(1): p. 66-74.

7. Gillman, PK, CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity. J Psychopharmacol (Oxf), 2011. 25(3): p. 429-3.

8. Finberg, J and Gillman, P, Pharmacology of MAO-B inhibitors and the cheese reaction, in Int. Rev. Neurobiol., M Youdim and P Riederer, Editors. 2011, Elsevier Inc. Academic Press.: Burlington. p. 169-190.

9. Ramsay, RR, Dunford, C, and Gillman, PK, Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol, 2007. 152(6): p. 946-51.

10. Gillman, PK, Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br. J. Anaesth., 2005. 95(4): p. 434-441.

11. Gillman, PK, “Much ado about nothing”: monoamine oxidase inhibitors, drug interactions, and dietary tyramine. CNS Spectr, 2017: p. 1-3.

12. Atchley, DW, Reevaluation of Tranylcypromine Sulfate. JAMA, 1964. 189: p. 763-4.

13. Lesse, S, Tranylcypromine (Parnate)–a study of 1000 patients with severe agitated depressions. Am. J. Psychother., 1978. 32(2): p. 220-42.

14. Atkinson, RM and Ditman, KS, Tranylcypromine: a review. Clin Pharmacol Ther, 1965. 6(5): p. 631-55.

15. Gillman, PK, Monoamine oxidase inhibitors: A review concerning dietary tyramine and drug interactions. PsychoTropical Commentaries, 2017. 17(1): p. 1-104 Available at:

Accessed May 2017.

16. Cole, J, Therapeutic Efficacy of Antidepressant Drugs. Journal of the American Medical Association, 1964.

17. Cole, JO and Bodkin, JA, MAO inhibitors: an option worth trying intreatment-resistantcases. Curr.Psychiatry, 2002. 1: p. 40-47.

18. Fiedorowicz, JG and Swartz, KL, The role of monoamine oxidase inhibitors in current psychiatric practice. J Psychiatr Pract, 2004. 10(4): p. 239-48.

19. Laux, G, Volz, H-P, and Möller, H-J, Newer and Older Monoamine Oxidase Inhibitors. CNS Drugs, 1995. 3(2): p. 145-158.

20. Schwartz, TL, A neuroscientific up date on monoamine oxidase and its inhibitors. CNS Spectr, 2013. 18(S1): p. 22–33.

21. Thase, ME, Trivedi, MH, and Rush, AJ, MAOIs in the contemporary treatment of depression. Neuropsychopharmacology, 1995. 12(3): p. 185-219.

22. Shulman, KI, Herrmann, N, and Walker, SE, Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression. CNS Drugs, 2013.

23. Wimbiscus, M, Kostenko, O, and Malone, D, MAO inhibitors: risks, benefits, and lore. Cleve. Clin. J. Med., 2010. 77(12): p. 859-82.

24. O’Brien, V, The Monoamine Oxidase Inhibitors: Relics Reconsidered. Psychiatr Ann, 2011. 41(3): p. 176-183.

25. Grady, MM and Stahl, SM, Practical guide for prescribing MAOIs: debunking myths and removing barriers. CNS Spectr, 2012. 17(1): p. 2-10.

26. Song, MS, Matveychuk, D, Mackenzie, EM, Duchcherer, M, et al., An Update on Amine Oxidase Inhibitors: Multifaceted Drugs. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2013.

27. Thomas, SJ, Shin, M, McInnis, MG, and Bostwick, JR, Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression. Pharmacotherapy, 2015. 35(4): p. 433-49.

28. Stahl, SM and Felker, A, Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr, 2008. 13(10): p. 855-70.

29. Meyer, JM, A concise guide to monoamine oxidase inhibitors: How to avoid drug interactions: Use these strategies to maximize efficacy and minimize adverse effects when prescribing an MAOI. Current Psychiatry, 2018. 17(1): p. 22.

30. Nolen, WA, When and how should we use monoamine oxidase inhibitors? 2018.

31. Menkes, D, Bosanac, P, and Castle, D, MAOIs-does the evidence warrant their resurrection? Australasian psychiatry: bulletin of Royal Australian and New Zealand College of Psychiatrists, 2016.

32. Larsen, JK, Krogh-Nielsen, L, and Brøsen, K, The Monoamine Oxidase Inhibitor Isocarboxazid is a Relevant Treatment Option in Treatment-Resistant Depression-Experience-Based Strategies in Danish Psychiatry. Danish Psychiatry. Health Care: Current Reviews, 2016. 4: p. 168. doi: 10.4172/2375-4273.1000168.

33. Israel, JA, Combining Stimulants and Monoamine Oxidase Inhibitors: A Reexamination of the Literature and a Report of a New Treatment Combination. Prim Care Companion CNS Disord, 2015. 17(6): p.

34. Klein, DF and Arden, PC, Early development of monoamine oxidase inhibitors. Psychiatr Ann, 2014. 44(12): p. 563-566.

35. Zetin, M, A Clinician’s Guide to Monoamine Oxidase Inhibitors. Current Psychiatry Reviews, 2013. 9(4).

36. Goldberg, JF and Thase, ME, Monoamine oxidase inhibitors revisited: what you should know. J Clin Psychiatry, 2013. 74(2): p. 189-91.

37. Thase, ME, The role of monoamine oxidase inhibitors in depression treatment guidelines. J Clin Psychiatry, 2012. 73 Suppl 1: p. 10-6.

38. Kosinski, EC and Rothschild, AJ, Increased knowledge of MAOIs has made these agents worthy of reconsideration. Current Psychiatry, 2012. 11(12): p. 21.

39. Costa, MJJ, Moyer, M, and O’Reardon, JP, Monoamine Oxidase Inhibitors: An Important but Underutilized Treatment: Part II: Safety and Tolerability. Psychopharm Review, 2012. 47(11): p. 81-87.

40. Pitchot, W, Scantamburlo, G, and Ansseau, M, [Tricyclic antidepressants and monoamine oxidase inhibitors – do they still have a role in the treatment of depression?]. Rev. Med. Liege, 2011. 66(3): p. 144-52.

41. Shulman, KI, Fischer, HD, Herrmann, N, Huo, CY, et al., Current prescription patterns and safety profile of irreversible monoamine oxidase inhibitors: a population-based cohort study of older adults. J Clin Psychiatry, 2009. 70(12): p. 1681-6.

42. Mallinger, AG, Frank, E, Thase, ME, Barwell, MM, et al., Revisiting the effectiveness of standard antidepressants in bipolar disorder: are monoamine oxidase inhibitors superior? Psychopharmacol. Bull., 2009. 42(2): p. 64-74.

43. Fawcett, J, Why aren’t MAOIs used more often? J Clin Psychiatry, 2009. 70(1): p. 139-40.

44. Krishnan, KR, Revisiting monoamine oxidase inhibitors. J Clin Psychiatry, 2007. 68 Suppl 8: p. 35-41.

45. Shaw, GB, Man and Superman. 1903.

46. Gillman, PK, More on Mrs Murphy’s beans: or ‘do us a fava’. J Clin Psychopharmacol, 2010. 30(2): p. 215-216.

47. Malhi, G and Berk, M, Does dopamine dysfunction drive depression? Acta Psychiatr. Scand., 2007. 115: p. 116-124.

48. Gillman, PK, A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry, 2006. 59(11): p. 1046-51.

49. Perugi, G, Vannucchi, G, Bedani, F, and Favaretto, E, Use of stimulants in bipolar disorder. Current psychiatry reports, 2017. 19(1): p. 7.

50. McIntyre, RS, Lee, Y, Zhou, AJ, Rosenblat, JD, et al., The Efficacy of Psychostimulants in Major Depressive Episodes: A Systematic Review and Meta-Analysis. J Clin Psychopharmacol, 2017. 37(4): p. 412-418.

51. Szmulewicz, AG, Angriman, F, Samame, C, Ferraris, A, et al., Dopaminergic agents in the treatment of bipolar depression: a systematic review and meta-analysis. Acta Psychiatr. Scand., 2017. 135(6): p. 527-538.

52. Parker, G and Brotchie, H, Do the old psychostimulant drugs have a role in managing treatment-resistant depression? Acta Psychiatr. Scand., 2010. 121(4): p. 308-14.

53. Parker, G, Brotchie, H, McClure, G, and Fletcher, K, Psychostimulants for managing unipolar and bipolar treatment-resistant melancholic depression: a medium-term evaluation of cost benefits. J Affect Disord, 2013. 151(1): p. 360-4.

54. Pristupa, ZB, Wilson, JM, Hoffman, BJ, Kish, SJ, et al., Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding. Mol Pharmacol, 1994. 45(1): p. 125-35.

55. Bymaster, FP, Katner, JS, Nelson, DL, Hemrick-Luecke, SK, et al., Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology, 2002. 27(5): p. 699-711.

56. Tatsumi, M, Groshan, K, Blakely, RD, and Richelson, E, Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol, 1997. 340(2-3): p. 249-58.

57. Zohar, J, Stahl, S, Moller, HJ, Blier, P, et al., A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. Eur. Neuropsychopharmacol., 2015. 25(12): p. 2318-25.

58. Nutt, DJ and Blier, P, Neuroscience-based Nomenclature (NbN) for Journal of Psychopharmacology. J Psychopharmacol, 2016. 30(5): p. 413-5.

59. Blier, P, Oquendo, MA, and Kupfer, DJ, Progress on the Neuroscience-Based Nomenclature (NbN) for Psychotropic Medications. Neuropsychopharmacology, 2017. 42(10): p. 1927-1928.

60. Gorwood, P, Frangou, S, Heun, R, and Editors-in-chief of European, P, Editorial: Neuroscience-based Nomenclature (NbN) replaces the current label of psychotropic medications in European Psychiatry. Eur Psychiatry, 2017. 40: p. 123.

61. Worley, L, Neuroscience-based nomenclature (NbN). Lancet Psychiatry, 2017. 4(4): p. 272-273.

62. Seifert, R, Rethinking Pharmacological Nomenclature. TiPS, 2018: p.

63. Feinberg, SS, Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. J Clin Psychiatry, 2004. 65(11): p. 1520-4.

64. Faraone, S, Spencer, T, Madras, B, Zhang-James, Y, et al., Functional effects of dopamine transporter gene genotypes on in vivo dopamine transporter functioning: a meta-analysis. Mol. Psychiatry, 2014. 19(8): p. 880.

65. Faraone, SV, The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci. Biobehav. Rev., 2018. 87: p. 255-270.

66. van Praag, H, Asnis, GM, Kahn, RS, Brown, SL, et al., Monoamines and Abnormal Behaviour. A Multi-Aminergic Perspective. Br J Psychiatry, 1990. 157: p. 723-734.

67. van Praag, HM and Korf, J, Retarded Depression and the Dopamine Metabolism. Psychopharmalogia (Berl), 1971. 19: p. 199-203.

68. Salamone, JD, Pardo, M, Yohn, SE, Lopez-Cruz, L, et al., Mesolimbic Dopamine and the Regulation of Motivated Behavior. Curr Top Behav Neurosci, 2016. 27: p. 231-57.

69. Hosking, JG, Floresco, SB, and Winstanley, CA, Dopamine antagonism decreases willingness to expend physical, but not cognitive, effort: a comparison of two rodent cost/benefit decision-making tasks. Neuropsychopharmacology, 2015. 40(4): p. 1005-15.

70. Boylan, LS and Kostić, VS, Don’t ask, don’t tell. Neurology, 2018.

71. Smith, GC and Pell, JP, Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ, 2003. 327(7429): p. 1459-61.

Apple Podcast
Visit Us
Follow Me
Research Gate
Google Scholar